Stock CSL CSL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News CSL Limited

Equities

CSL

AU000000CSL8

Delayed Australian S.E.
Other stock markets
 12:34:06 2024-04-19 am EDT 		5-day change 1st Jan Change
269.1 AUD -0.84% Intraday chart for CSL Limited -4.47% -6.12%
Apr. 10 Miners boost Australian shares; NZ cenbank keeps rates steady RE
Apr. 10 New Zealand shares hold gains as c.bank expectedly holds rate; Aussie shares up RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build “Australia’s next CSL”
PU
Miners boost Australian shares; NZ cenbank keeps rates steady
RE
New Zealand shares hold gains as c.bank expectedly holds rate; Aussie shares up
RE
Australian shares rise on mining and healthcare boost; US CPI data, RBNZ in focus
RE
Australian shares end higher as miners surge; US CPI in focus
RE
Australian shares fall as financials and healthcare stocks drag
RE
Australian shares hit record high; RBA cautious on inflation
RE
Australian shares inch higher; inflation data reinforces subdued rate-cut view
RE
CSL Prices $1.25 Billion Corporate Bonds Offering
MT
Miners, healthcare firms push Australia stocks higher
RE
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
AQ
Australian shares fall as miners, banks weigh
RE
Ex-dividend day for interim dividend
FA
Banks drive Australian shares to record high on firming rate-cut bets
RE
CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee
CI
Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight
MT
Australia Health Stocks to Remain at Premium to ASX200, Morgan Stanley Says
MT
Australian shares skid off record highs to end lower; GDP data awaited
RE
Australian shares end marginally up as energy, financials offset weak miners
RE
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CSL Stock
  4. News CSL Limited